Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
The clinical, genetic or biological variables which regulate long-term efficacy of cholinesterase inhibitors (ChEIs) in Alzheimer disease (AD) are still unknown and it is not possible to predict who will benefit from the treatment. In this study we showed that high cholesterol levels correlated with faster decline at 1-year follow-up in AD patients on ChEIs. These findings suggest that serum cholesterol is a modulating factor of treatment response and additional therapies aimed at reducing treatable high cholesterol levels may represent an alternative strategy to improve ChEIs efficacy and slow down disease progression over time.
Borroni
Barbara
B
Department of Medical Sciences, Neurological Clinic, University of Brescia, P.za Spedali Civili, 1, 25100 Brescia, Italy.
Pettenati
Carla
C
Bordonali
Tania
T
Akkawi
Nabil
N
Di Luca
Monica
M
Padovani
Alessandro
A
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000188:drug therapy* / Q000523:psychology; D001057:Apolipoproteins E / Q000235:genetics; D002219:Carbamates / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D018450:Disease Progression; D000077265:Donepezil; D005260:Female; D005838:Genotype; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use; D000068836:Rivastigmine
D001057:Apolipoproteins E; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D002784:Cholesterol; D000068836:Rivastigmine